Aberdeen Group Expands Stake in uniQure with Strategic Acquisition

Aberdeen Group plc acquired 535,163 shares of uniQure NV at $13.94 per share, increasing its stake in the biotechnology company by 24.15%. This strategic investment reflects Aberdeen Group's focus on expanding its position in the gene therapy sector. uniQure NV, with a market cap of $740.155 million, is a leading gene therapy company developing treatments for genetic and severe diseases. Despite current challenges, Aberdeen Group's confidence in uniQure NV's long-term potential may indicate a strategic long-term investment.